Several studies, including ours, have demonstrated that high MRD levels, which are indicated by less than a 3‐log reduction of RUNX1‐RUNX1T1 transcript levels during treatment, were poor prognostic factors, although the significant time points were different among the studies.4, 5, 6 In addition, c‐KIT mutation was found to be the most prevalent mutation in t(8;21) AML and has been demonstrated to be related to poor outcomes by many studies.7, 8, 9 However, the specificity and sensitivity of the current risk stratification are not perfect. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.